Precigen Actobio

Foundation date

03/07/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.

We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.

Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.

Upcoming events

Latest news

  • Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera

    Friday February 3rd 2023

  • Weber joins Vivactis Group to reinforce its Market Access capabilities

    Thursday February 2nd 2023

  • Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health

    Thursday February 2nd 2023

Jobs by Precigen Actobio